title: A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition.
abstract: This multicenter, double-blind, randomized study was designed to compare the effects of simvastatin (20 mg/d and 40 mg/d) and fenofibrate (400 mg/d) on plasma lipids, lipoproteins, apolipoproteins (apo), and lipoprotein particles defined by their apo composition (Lp A-I, Lp A-II:A-I, Lp E:B, Lp C-III:B) in primary hypercholesterolemia. After 6 and 10 weeks of therapy, both drugs lowered plasma cholesterol, low-density lipoprotein (LDL) cholesterol, and apo B. The effect on LDL and apo B was significantly more pronounced for simvastatin (P = .01). Simvastatin increased Lp A-I, but did not change Lp A-II:A-I, while fenofibrate decreased Lp A-I and increased Lp A-II:A-I. Lp E:B and Lp C-III:B were decreased with both drugs, but fenofibrate was significantly more effective in reducing these particles than simvastatin. This study demonstrates that both drugs have beneficial effects on the parameters positively or negatively correlated with the atherosclerotic risk, with simvastatin being more effective in reducing some of them. These results suggest that the drugs led to different structural modifications of the lipoproteins, which would not be revealed by examination of lipoprotein density classes. These differences are probably related to the different mechanisms of action of the agents.
authors.affiliation: Serlia, INSERM U325, Institut Pasteur, Lille, France.
authors.forename: J M
authors.initials: JM
authors.lastname: Bard
authors.forename: H J
authors.initials: HJ
authors.lastname: Parra
authors.forename: R
authors.initials: R
authors.lastname: Camare
authors.forename: G
authors.initials: G
authors.lastname: Luc
authors.forename: O
authors.initials: O
authors.lastname: Ziegler
authors.forename: C
authors.initials: C
authors.lastname: Dachet
authors.forename: E
authors.initials: E
authors.lastname: Bruckert
authors.forename: P
authors.initials: P
authors.lastname: Douste-Blazy
authors.forename: P
authors.initials: P
authors.lastname: Drouin
authors.forename: B
authors.initials: B
authors.lastname: Jacotot
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D001053:Apolipoproteins / Q000097:blood*; D002784:Cholesterol / Q000097:blood; D005260:Female; D011345:Fenofibrate / Q000627:therapeutic use*; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D066298:In Vitro Techniques; D008074:Lipoproteins / Q000097:blood*; D008148:Lovastatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D019821:Simvastatin
chemical_list: D000924:Anticholesteremic Agents; D001053:Apolipoproteins; D008074:Lipoproteins; D002784:Cholesterol; D008148:Lovastatin; D019821:Simvastatin; D011345:Fenofibrate